Clinical factors associated with growth and neoantigen reactivity of tumor infiltrating lymphocytes from metastatic epithelial cancers
Prior immune checkpoint therapies reduced the likelihood of having highly reactive TIL. Neoantigen reactivity was more common in TIL from thoracic resections versus other sites. Conversely, hepatic lesions yielded TIL less likely to grow and with less reactivity. These results contribute to improved strategies for sequencing TIL with other therapies and planning TIL harvests for patients with epithelial cancers.
Authors
- Mei Li M. Kwong (ORCID: https://orcid.org/0000-0003-1265-520X)
- Nicholas D. Klemen (ORCID: https://orcid.org/0000-0003-1353-539X)
- Jonathan M. Hernandez (ORCID: https://orcid.org/0000-0001-7529-0557)
- James Chih‐Hsin Yang (ORCID: https://orcid.org/0000-0002-5586-5138)
- Maria R. Parkhurst (ORCID: https://orcid.org/0000-0001-7231-5069)
- Aaron J Dinerman (ORCID: https://orcid.org/0009-0008-8670-8347)
- Kyle Hitscherich (ORCID: https://orcid.org/0000-0001-8081-356X)
- Stephanie L. Goff (ORCID: https://orcid.org/0000-0003-3317-9804)
- Hyunmi Halas (ORCID: https://orcid.org/0009-0007-3933-6459)
- Chuong D. Hoang (ORCID: https://orcid.org/0000-0003-4016-1434)
- Steven A. Rosenberg (ORCID: https://orcid.org/0000-0002-4344-3608)
- Donald E. White
- Alexandra Gustafson
Institutions
- National Institutes of Health (US)
- National Cancer Institute (US)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2025-06-19
- DOI
- https://doi.org/10.1007/s00262-025-04091-3
- Citations
- 2
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- National Institutes of Health
- NIH Clinical Center